M&A Deal Summary |
|
---|---|
Date | 2015-10-14 |
Target | Blyth |
Sector | Consumer Products |
Buyer(s) | The Carlyle Group |
Deal Type | Going Private |
Deal Value | 98M USD |
Advisor(s) | Houlihan Lokey (Financial) Wachtell, Lipton, Rosen & Katz (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Private Equity Firm |
---|---|
Founded | 1987 |
PE ASSETS | 435.0B USD |
Size | Mega |
Type | Sector Agnostic |
The Carlyle Group is a global investment firm that pursues private equity, credit, and real estate investments worldwide. Carlyle's private equity practice practice pursues buyouts, strategic minority equity investments, equity private placements, consolidations and buildups, and growth capital financings. With offices in 19 countries, Carlyle can easily target opportunities throughout North America, Europe, Asia, Australia, the Middle East/North Africa and Latin America. Broad sectors of interest include aerospace, defense, automotive and transportation, consumer, retail, energy and power, financial services, healthcare, industrial, infrastructure, technology services, business services, telecommunications and media. The Carlyle Group was formed in 1987 and is based in Washington DC.
DEAL STATS | # |
---|---|
Overall | 545 of 742 |
Sector (Consumer Products) | 18 of 22 |
Type (Going Private) | 28 of 35 |
State (Connecticut) | 7 of 7 |
Country (United States) | 275 of 348 |
Year (2015) | 35 of 41 |
Size (of disclosed) | 120 of 136 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-10-08 |
Athena Art Finance
New York, New York, United States Athena Art Finance Corp. is a specialty finance lender, dedicated to providing loans collateralized by fine art. Athena offers a full-service platform focused on debt origination, portfolio management and distribution of art-backed credit risk globally. Athena Art Finance Corp. was formed in 2015 and is based in New York. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-10-19 |
AqueSys
Aliso Viejo, California, United States AqueSys, Inc. is a developer of surgical products for the treatment of glaucoma. The company's device acts as a drainage shunt to lower intraocular pressure to relieve symptoms of glaucoma. |
Sell | $300M |